Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

British Journal of Clinical Pharmacology

Volumn 46, Issue 1, 1998, Pages 49-53

  Kivisto K T ^a   Kantola, T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Fluvastatin; Interaction; Itraconazole; Lovastatin; Pharmacokinetics

Indexed keywords

FLUINDOSTATIN; ITRACONAZOLE; MEVINOLIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENTIATION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTICHOLESTEREMIC AGENTS; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INCOMPATIBILITY; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; ITRACONAZOLE; LOVASTATIN; MALE;

EID: 0031803373     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00034.x     Document Type: Article

References (21)

1. Duggan DE, Chen IW, Bayne WF, et al. The physiological disposition of lovastatin. Drug Metab Dispos 1989; 17: 166-173.
2. Wang RW, Kan PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin. IV. Identification of cytochrome P450, 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290: 355-361.
3. Transon C, Leemann T, Dayer P. Selective in vitro P450 inhibition profile by fluvastatin indicates its potential in vivo drug interactions. Clin Pharmacol Ther 1993; 53: 188.
4. Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±) -fluvastatin. Clin Pharmacol Ther 1995; 58: 412-417.
5. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin. N Engl J Med 1988; 318: 46-47.
6. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J.
7. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-665.
8. Marinella MA. More on lovastatin. West J Med 1995; 162: 176-177.
9. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61.
10. Stubbs RJ, Schwanz M, Bayne WF. Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. J Chromatogr 1986; 383: 438-443.
11. Toreson H, Eriksson B-M. Liquid chromatographic determination of fluvastatin and its enantiomers in blood plasma by automated solid-phase extraction. Chromatographia 1997; 45: 29-34.
12. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 1990; 532: 203-206.
13. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet 1997; 32: 403-425.
14. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559-1564.
15. Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523-530.
16. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.
17. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krahenbuhl S. Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity. Schweiz Med Wochenschr 1995; 125: 1342-1346.
18. Horn M. Coadimnistration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 1996; 132: 1254.
19. Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996; 11: 1846-1847.
20. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997; 277: 296-297.
21. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatm is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341.